| Literature DB >> 36233164 |
N Sanoj Rejinold1, Goeun Choi1,2,3, Jin-Ho Choy1,4,5,6.
Abstract
Clay-based bio-inorganic nanohybrids, such as layered double hydroxides (LDH), have been extensively researched in the various fields of biomedicine, particularly for drug delivery and bio-imaging applications. Recent trends indicate that such two-dimensional LDH can be hybridized with a variety of photo-active biomolecules to selectively achieve anti-cancer benefits through numerous photo/chemotherapies (PCT), including photothermal therapy, photodynamic therapy, and magnetic hyperthermia, a combination of therapies to achieve the best treatment regimen for patients that cannot be treated either by surgery or radiation alone. Among the novel two-dimensional clay-based bio-inorganic nanohybrids, LDH could enhance the photo-stability and drug release controllability of the PCT agents, which would, in turn, improve the overall phototherapeutic performance. This review article highlights the most recent advances in LDH-based two-dimensional clay-bio-inorganic nanohybrids for the aforementioned applications.Entities:
Keywords: clay nanoparticles; combined photochemotherapy; future directions; inorganic bio-nanohybrids; phototherapy
Mesh:
Substances:
Year: 2022 PMID: 36233164 PMCID: PMC9569973 DOI: 10.3390/ijms231911862
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Scheme 1Layered double hydroxides, built from sheets of [MII1−x MIIIx(OH)2]x+ octahedral units intercalated with anions (large blue spheres). Each octahedron is composed of a metal cation (MII or MIII), coordinated with six OH− ligands (small blue spheres).
Scheme 2Novel two-dimensional bio-nanohybridization strategies for photochemotherapy applications. (A: 2D clay-based building block that is primarily LDH; B: PTT agents; C-PDT agents and D: PTT, PDT, and chemo agents).
Various clay-based bio-inorganic nanohybrids in photothermal, photodynamic, photothermal/photodynamic, and chemo-combination therapies.
| Clay Hybrids | Phototherapeutic Agent or Chemo Drug Used | Applications | Physico/Chemical | Preparation Method | Remarks | Ref. |
|---|---|---|---|---|---|---|
| Co-Fe-LDH | Co | PTT, NIR, MRI, and PAI | The TEM image of CoFe-LDH revealed nanosheets with a characteristic hexagonal morphology and a lateral size of 200 ± 20 nm. | Sintering at 200–800 °C under an Ar atmosphere | Theranostic | [ |
| B3int, DOX, and ICG loaded in LDH | ICG and DOX | PTT and Chemo | 80 nm sized LDH NPs | LDH NPs were prepared by a hydrothermal method followed by surface modification of the LDH NPs with H2N-PEG-NH2. The targeting peptide B3int was introduced through an amide condensation reaction and finally, DOX and ICG were loaded using a physical adsorption method | Targeted cancer therapy and PTT | [ |
| Fe-LDH | Fe-LDH/DOX | MRI, PTT, and chemo | Photothermal conversion efficiency of 45.67% with good stability and pH sensitivity | Doping of ferrous ions into Fe-LDH and DOX loading through physical methods | In vivo results on 4T1 tumor model proved its theranostic properties | [ |
| DOX/ICG-CpG-LDH | ICG and DOX | PTT-Chemo-Immuno therapy | The average particle size (DLS) increased from 84 nm (LDH) to 120 nm (BSA coated-LDH) at the BSA/LDH mass ratio of 5:2 | Solution mixing | Theranosis toward breast cancers | [ |
| Isophthalic acid (IPA)/LDH nanohybrids | Isophthalic acid | PDT | The tapping mode AFM image demonstrates ~50 nm diameter and ~4 nm thickness of IPA/LDH, confirming the formation of ultrathin nanosheets | Co-precipitation method | Combined PDT/chemotherapy | [ |
| Ce6/Pt(IV)-LDH | PDT/Chemo | Combined PDT and Chemo | Average hydrodynamic size for LDH is 52 ± 2 nm; the size increases to 150 ± 7, 184 ± 3, and 2633 ± 685 nm for Ce6-Pt(IV)/LDH with the Ce6:Pt(IV) of 0.81, 1.92, and 4.99, respectively | LDH was prepared by hydrothermal method and the Ce6 and Pt(IV) were loaded by anion-exchange reaction | Combined PDT and Chemo approach cisplatin-resistant human cancer cells | [ |
| Fe-Mn-LDH | Methylene blue | PTT/PDT | It has 2D nanosheet structure with particle size of about 200 nm and thickness of 2.8 nm comprising 2–3 layers with good dispersibility in water and cell culture medium, with an average hydrated particle size of about 220 nm/zeta potential of −25.4 mV in water and exhibits good stability in both water and cell culture medium | Co-precipitation method | Improved efficacy on U14 tumor model | [ |
| LIPC[a] nanosheets | CCM, ICG, and PTX loaded with LDHs | Combined PDT and Chemo | TEM images reveal that LI possessed a typical hexagonal plate-like morphology, with the particle lateral dimension in the range from 50 to 100 nm. After loading PTX-BSA/BSA and coating CCM, LIPC displayed a core–shell structure with a shell of 6–10 nm in length | Physical mixing | Theranostic approach to treat colorectal cancers | [ |
| ICG/Cu-LDH@BSA−DOX | ICG, Cu, and DOX | Dual phototherapy and imaging | Hydrodynamic diameter and the zeta potential of Cu-LDH NPs in deionized water were measured to be 58.4 ± 2.5 nm and 37.0 ± 0.6 mV, respectively. The hybrids were in the range of ~200 nm | Physical mixing | Theranostic applications at lower dosage | [ |
| Fe-Mn-LDH | Ce6 and mesoporous silica | Trimodal therapy | The Ce6 and silica coating on UCNPs@Ce6@mSiO2 (UCS) possesses an average diameter of 47 nm. The pure FeMn-LDH exhibits a 2D ultrathin structure and hexagon structure comprising several layers with the size of ≈100 nm. After anchoring with UCSP NPs, it can be observed that UCSP can be anchored on the FeMn-LDH nanosheets with an increased size of ≈200 nm with good monodispersity. The DLS particle sizes of UCSP, FeMn-LDH, and UCSP-LDH are 58.8, 130, and 230 nm, respectively with excellent stability in both water and cell culture medium after two days’ standing | Physical mixing | The trimodal theranostic approach was validated on a U14-bearing tumor model | [ |
| d-Cu-LDH/ICG | d-Cu-LDH and ICG | Trimodal therapy | Cu-LDH, d-Cu-LDH, and LDH/ICG NPs showed typical plate-like morphology with almost the same particle size distribution with the average hydrodynamic particle size from 25.9 ± 1.1 to 38.8 ± 1.8 nm and zeta potential of around 34–35 mV | Intercalation of ICG into the interlayers of d-Cu-LDH | PTT and PDT-Chemo | [ |
Abbreviations: LDH, layered double hydroxide; PTT, photothermal therapy; NIR, near-infrared; MRI, magnetic resonance imaging; PAI, photoacoustic imaging; B3int, arginine-tryptophan-(D-arginine)-asparagine-arginine; DOX, doxorubicin; ICG, indocyanine green; PDT, photodynamic therapy; CCM, cancer cell membrane; PTX, paclitaxel; LIPC, LDH-ICG/PTX-CCM; BSA, bovine serum albumin; CDT, chemodynamic therapy; PTT, photothermal therapy; IPA, Isophthalic acid; Ce6, chlorin e6; 4T1, breast cancer cell line derived from the mammary gland tissue of a mouse BALB/c strain; U14- squamous mouse carcinoma.
Figure 1(a) Synthesis scheme of gold nanorods (GNR)@layered double hydroxide (LDH) (copyright from ACS-2019). (b) Novel two-dimensional (2D) bio-nanohybridization strategies for photochemotherapy applications. Schematic illustration of the synthesis of doxorubicin (DOX)-indocyanine green (ICG) and LDH-PEG-B3int((arginine-tryptophan-(D-arginine)-asparagine-arginine)) nanoparticles (copyright from Elsevier, 2019). (c) Illustration of nanohybrids as two-photon photosensitizers for 1O2 generation. Schematic representation of the LDH host and five aromatic RTP guest species. Two-dimensional-confined long-lived triplet excitons can function as photosensitizers to achieve efficient 1O2 generation under 808 nm near-infrared laser power (copyrights under Creative Commons Attribution 4.0 International License, Nature, 2018). (d) Overview of the strategy to co-deliver the Pt(IV) prodrug, DSCP (c,c,t-(diamminedichlorodisuccinato) Pt (IV), and the photosensitizer, Ce6 (chlorin e6), using LDH nanoparticles. (e) Synthetic steps involved in the development of trimodal photothermal therapy/photodynamic chemotherapy using d-Cu-LDH/ICG nanohybrids.
Scheme 3Schematic representation of a multifunctional inodocyanin green (ICG)/Dox/DNA/CpG/BSA-LDH (IDCB)-layered double hydroxide (LDH) nanomedicine. (a) This hybrid nanomedicine was constructed via initial coating with bovine serum albumin (BSA) and then orderly loading with indocyanine green (ICG), the doxorubicin (DoX)/DNA prodrug, and CpG ODN (oligodeoxynucleotide) 1826. (b) IDCB-LDH, with 808 nm NIR irradiation, heats the tumor tissues and releases DoX at a temperature above 41 °C, yielding anti-tumor effects through efficient photothermal therapy and the subsequent CTX (chemotherapy), which then results in sufficient tumor antigens and stimulates the secretion of pro-tumor cytokines. The residual ICB-LDH in the tumor tissue further acts as a nano-adjuvant and adsorbs the in situ-generated tumor antigens to mature and stimulate DCs (dendritic cells). (c) Mature DCs activate naïve T Cells in the dLNs (draining lymph nodes) and induce potent cytotoxic T lymphocytes (CTLs), namely, CD8+ T Cells. The CTLs subsequently migrate to the distant tumor tissues and the metastatic tumor nodules in the lung to eliminate the tumor cells. The CTLs increase, while the regulatory T cells decrease, in the distant and metastatic tumors (Reprinted/adapted with permission from Ref. [64]. Copyright 2019, American Chemical Society).
Scheme 4Schematic illustration of a multifunctional indocyanine green (ICG)/Cu-layered double hydroxide (LDH)@BSA–doxorubicin (DOX) nanomedicine. (a) Hybrid LDH nanoparticles constructed by making Cu-LDH, loading ICG, and then coating with BSA/BSA–DOX. (b) Mice bearing B16F0 tumors are intravenously injected with ICG/Cu-LDH@BSA–DOX and exposed to 808-nm laser irradiation (0.3 W cm−2 for 2 min) after 24 h injection, at considerably lower doses (DOX: 0.175 mg kg−1, Cu: 0.5 mg kg−1, and ICG: 0.25 mg kg−1) than those usually used. (c) BSA/BSA–DOX-coated ICG/Cu-LDH nanoparticles efficiently accumulate in the tumor site via the EPR effect and facilitate the uptake of tumor cells via the clathrin-mediated endocytosis pathway. In the late endosome, LDH nanoparticles that were neutralized with pumped-in H+ ions led to an increased number of Mg2+, Al3+, and Cl– ions. An increase in the ionic strength within the endosome drove the water molecules into the endosome, resulting in the osmotic swelling of the endosome and the eventual release of the residual LDH nanoparticles into the cytoplasm. Once internalized by B16F10 cancer cells, ICG/Cu-LDH@BSA–DOX releases therapeutic DOX in response to an acidic environment (pH 5.0–6.5), which synergizes with near-infrared irradiation-induced photothermal therapy (PTT)/photodynamic therapy (PDT) to enable tumor apoptosis. (d) The mechanism of pH-triggered DOX release involves amide bond cleavage under a mildly acidic microenvironment of tumor tissues and cells.(Reprinted/adapted with permission from Ref. [69]. 2021, American Chemical Society).